留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

DNA甲基化调控的MicroRNA在乳腺癌中的研究进展

邓南星

邓南星. DNA甲基化调控的MicroRNA在乳腺癌中的研究进展[J]. 分子影像学杂志, 2014, 37(3): 190-192. doi: 10.3969/j.issn.1674-4500.2014.03.22
引用本文: 邓南星. DNA甲基化调控的MicroRNA在乳腺癌中的研究进展[J]. 分子影像学杂志, 2014, 37(3): 190-192. doi: 10.3969/j.issn.1674-4500.2014.03.22
Nanxing Deng. Research advance of DNA methylation regulation of miRNAs in breast carcinoma[J]. Journal of Molecular Imaging, 2014, 37(3): 190-192. doi: 10.3969/j.issn.1674-4500.2014.03.22
Citation: Nanxing Deng. Research advance of DNA methylation regulation of miRNAs in breast carcinoma[J]. Journal of Molecular Imaging, 2014, 37(3): 190-192. doi: 10.3969/j.issn.1674-4500.2014.03.22

DNA甲基化调控的MicroRNA在乳腺癌中的研究进展

doi: 10.3969/j.issn.1674-4500.2014.03.22
详细信息
    作者简介:

    邓南星, 在读硕士研究生, 研究方向:恶性肿瘤的发病机制及防治, E-mail:514869019@qq.com

Research advance of DNA methylation regulation of miRNAs in breast carcinoma

  • 摘要: 微小核糖核酸(miRNA)是一类内源性非编码小RNA, 长约18~25个核苷酸, 其通过与特定靶mRNA结合来抑制mRNA翻译过程, 从而在转录后水平调节靶基因的表达水平, 与恶性肿瘤的发生、发展、侵袭以及转移密切相关。前期大量研究发现, DNA甲基化可能是调控乳腺癌中miRNA表达异常的机制, 包括癌基因miRNA低甲基化激活和抑癌基因miRNA高甲基化失活, 从而导致miRNA调控的下游靶基因表达异常, 参与乳腺癌的发生发展。因此, 本文主要就DNA甲基化调控的miRNA在乳腺癌中的研究进展作一综述。

     

  • [1] Johnston SR.New strategies in estrogen receptor-positive breast cancer[J].Clin Cancer Res, 2010, 16:1979-87. doi: 10.1158/1078-0432.CCR-09-1823
    [2] Bardhan K, Liu K.Epigenetics and colorectal cancer pathogenesis[J].Cancers (Basel), 2013, 5(2):676-713. doi: 10.3390/cancers5020676
    [3] Li BQ, Yu H, Wang Z, et al.MicroRNA mediated network and DNA methylation in colorectal cancer[J].Protein Pept Lett, 2013, 20(3): 352-63. https://www.ncbi.nlm.nih.gov/pubmed/22591477
    [4] Puszyk WM, Trinh TL, Chapple SJ, et al.Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma[J].Lab Invest, 2013, 93(9):983-90. doi: 10.1038/labinvest.2013.94
    [5] Jung EJ, Kim IS, Lee EY, et al.Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer[J].Ann Lab Med, 2013, 33(6):431-40. doi: 10.3343/alm.2013.33.6.431
    [6] Osman A.MicroRNAs in health and disease--basic science and clinical applications[J].Clin Lab, 2012, 58(5/6):393-402. https://www.ncbi.nlm.nih.gov/pubmed/22783567
    [7] Pasquinelli AE.MicroRNAs and their targets:recognition, regulation and an emerging reciprocal relationship[J].Nat Rev Genet, 2012, 13(4):271-82. https://www.ncbi.nlm.nih.gov/pubmed/22411466
    [8] Lagos-Quintana M, Rauhut R, Yalcin A, et al.Identification of tissue-specific microRNAs from mouse[J].Curr Biol, 2002, 12(9): 735-9. doi: 10.1016/S0960-9822(02)00809-6
    [9] Catto JW, Alcaraz A, Bjartell AS, et al.MicroRNA in prostate, bladder, and kidney cancer:a systematic review[J].Eur Urol, 2011, 59(5):671-81. doi: 10.1016/j.eururo.2011.01.044
    [10] Iorio MV.Croce CMmicroRNA involvement in human cancer[J]. Carcinogenesis, 2012, 33(6):1126-33. doi: 10.1093/carcin/bgs140
    [11] Kong YW, Ferland-Mccollough D, Jackson TJ.microRNAs in cancer management[J].Lancet Oncol, 2012, 13(6):E249-58. doi: 10.1016/S1470-2045(12)70073-6
    [12] Lu J, Getz G, Miska EA, et al.MicroRNA expression profiles classify human cancers[J].Nature, 2005, 435(743):834-8. https://www.ncbi.nlm.nih.gov/pubmed/15944708
    [13] Ferdin J, Kunej T, Calin G.Non-coding RNAs:identification of cancer-associated microRNAs by gene profiling[J].Technol Cancer Res Treat, 2010, 9(2):123-38. doi: 10.1177/153303461000900202
    [14] Sproul D, Meehan RR.Genomic insights into cancer-associated aberrant CpG island hypermethylation[J].Brief Funct Genomics, 2013, 12(3):174-90. doi: 10.1093/bfgp/els063
    [15] Liu WR, Shi YH, Peng YF, et al.Epigenetics of hepatocellular carcinoma:a new horizon[J].Chin Med J (Engl), 2012, 125(13): 2349-60. https://www.ncbi.nlm.nih.gov/pubmed/22882861
    [16] You JS, Jones PA.Cancer genetics and epigenetics:two sides of the same coin[J].Cancer Cell, 2012, 22(1):9-20. doi: 10.1016/j.ccr.2012.06.008
    [17] Saito Y, Liang G, Egger G, et al.Specific activationof microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells[J].Cancer Cell, 2006, 9(6):435-43. doi: 10.1016/j.ccr.2006.04.020
    [18] Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, et al.miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours[J].EMBO Mol Med, 2012, 4(11):1214-29. doi: 10.1002/emmm.201201483
    [19] Morita S, Takahashi RU, Yamashita R, et al.Genome-Wide analysis of DNA methylation and expression of MicroRNAs in breast cancer cells[J].Int J Mol Sci, 2012, 13(7):8259-72. https://www.ncbi.nlm.nih.gov/pubmed/22942701
    [20] Zhang Y, Yang P, Sun T, et al.miR-126 and miR-126*repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis[J].Nat Cell Biol, 2013, 15(3):284-94. doi: 10.1038/ncb2690
    [21] Baer C, Claus R, Plass C.Genome-Wide epigenetic regulation of miRNAs in cancer[J].Cancer Res, 2013, 73(2):473-7. doi: 10.1158/0008-5472.CAN-12-3731
    [22] Ng EK, Li R, Shin VY, et al.MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells[Z], 2013. https://www.ncbi.nlm.nih.gov/pubmed/24218337
    [23] Sandhu R, Rivenbark AG, Coleman WB.Loss of posttranscriptional regulation of DNMT3b by microRNAs:a possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines[J].Int J Oncol, 2012, 41(2):721-32. https://www.ncbi.nlm.nih.gov/pubmed/22664488/
    [24] Matsubara N.Epigenetic regulation and colorectal cancer[J].Dis Colon Rectum, 2012, 55(1):96-104. doi: 10.1097/DCR.0b013e318233a1ef
    [25] Gonzalez CA, Agudo A.Carcinogenesis, prevention and early detection of gastric cancer:Where we are and where we should go[J].Int J Cancer, 2012, 130(4):745-53. doi: 10.1002/ijc.v130.4
    [26] Ma XT, Wang YW, Zhang MQ, et al.DNA methylation data analysis and its application to cancer research[J].Epigenomics, 2013, 5(3):301-16. doi: 10.2217/epi.13.26
  • 加载中
计量
  • 文章访问数:  506
  • HTML全文浏览量:  214
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-04-01
  • 刊出日期:  2014-07-01

目录

    /

    返回文章
    返回

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者:

    为了缩短出版时滞,促进科研成果的快速传播,我刊自2024年1月起,刊期由双月刊变更为月刊。本刊主要栏目有:基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱!

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日